Guardant Complete leads the way in precision oncology testing.
Our proprietary, cutting-edge technology measures changes in circulating tumor DNA (ctDNA) to1:
- +
Get a highly sensitive, minimally invasive
assessment of cancer11 - +
Detect spatial and temporal evolution of a tumor12
The Guardant Complete
portfolio is backed by data from:
>300,000patients tested
>80 clinical outcomes
studies
>350 peer-reviewed
publications
A wide array of precision oncology assays and comprehensive support, all conveniently accessible in one, intuitive portal.
Partner with Guardant Complete and experience seamless
customer service, including:
- +
One intuitive portal to conveniently order
all tests - +
End-to-end billing assistance with Guardant Access
- +
Mobile phlebotomy for convenient sample collection
- +
On-demand support from Guardant Health Medical Affairs
Guardant Complete can transform how
you make critical treatment decisions
across the cancer continuum.3,9
SWIPE TO REVEAL FULL TABLE
First liquid-only biopsy for minimal residual disease (MRD) detection in early-stage settings.3
Explore product ›
First FDA-approved liquid-only comprehensive genomic profiling (CGP) for advanced-stage treatment selection.1,5
Explore product ›
Liquid-only CGP test for treatment selection in patients who have progressed on therapy.7
Explore product ›Important Note: Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 tests were developed, and performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. Guardant Reveal, Guardant360 TissueNext, Guardant360 Response, and Guardant360 are Laboratory Developed Tests (LDT). These tests have not been cleared or approved by the US FDA.
*Patient timeline is for illustrative purposes only.
†Confirmation of medical necessity is required if Guardant360 TissueNext is ordered with another Guardant Health profiling test.
HRR, homologous recombinational repair; MSI, microsatellite instable; NTRK, neurotrophic tyrosine receptor kinase; PD-L1, programmed death-ligand 1; TMB, tumor mutation burden.